AHA Statement Emphasizes Multidisciplinary Antiplatelet Management in Coronary Disease

An American Heart Association scientific statement published in Circulation reviews contemporary evidence informing antiplatelet therapy for patients with acute coronary syndrome and chronic coronary disease. It addresses how advances in stent technology, pharmacotherapy, procedural techniques, and risk stratification since the mid-2000s have supported increasingly individualized treatment strategies.

The statement emphasizes tailoring antiplatelet agent selection, intensity, and duration to patient-, procedure-, and disease-specific factors rather than using a uniform approach. It identifies complex evidence, frequent care transitions, social determinants of health, and patient variability as contributors to inappropriate prescribing, nonadherence, and adverse outcomes. Interventional cardiologists, general cardiologists, pharmacists, and advanced practice nurses are highlighted as key participants in antithrombotic stewardship.

For clinicians, the central message is to combine individualized assessment of thrombotic and bleeding risks with coordinated multidisciplinary management. This is a scientific statement, not a new clinical trial. The available abstract provides no quantitative outcome estimates or specific drug regimens, and full-text recommendations were not available for assessment.